

*A MIM depicting intramolecular domains, their modifications and molecular interactions:*

*Activation of src by EGFR*

Src has the following domains:


SH3: binds to proline-rich domains

SH2: binds to phosphotyrosine motifs


Pro: proline-rich domain

kinase: tyrosine kinase domain


The SH3 domain binds the Pro domain.




The Src tail region can be phosphorylated at Tyr 527.




The SH2 domain binds to the tyrosine-phosphorylated tail.




The 2 intra-molecular bonds form cooperatively, and fold the Src molecule, hiding the kinase domain and keeping Src in an inactive configuration.




Src binds to plasma membrane through a myristyl group.




# Src's tyrosine kinase domain could phosphorylate various substrates




Phosphorylation of Tyr416 is required for the kinase to be active.



# Activated (phosphorylated) EGFR could phosphorylate Tyr416




However, access to Tyr416 is blocked by the intra-molecular folding.




# SRC activation:


Through one of its phosphotyrosines, activated EGFR recruits p85.



# Pro domain of p85 competes with Pro of Src for binding to SH3 of Src




# Phosphotyrosine of EGFR competes with P-Tyr527 of Src for binding to SH2 of Src



Then EGFR can phosphorylate Tyr416  
 If binding is to EGFR, then this inhibition is relieved  
 And activate SRC

Substrates ← PY

With Tyr527 gone, Src cannot refold and remains active even if it dissociates from the EGFR:p85 complex.  
 Then a phosphatase can remove Tyr527 ...  
 Thus multiple Src's can be activated by a single active EGFR -- *i.e.*, an amplification step.





# Summary of src activation (no need to press any key)

